Welcome to our dedicated page for AVRX news (Ticker: AVRX), a resource for investors and traders seeking the latest updates and insights on AVRX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AVRX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AVRX's position in the market.
Avere Therapeutics announced a $500 million private placement from a syndicate of healthcare-focused institutional investors to support development of its once-weekly oral IL-23 receptor antagonist AVR-001. This financing is in addition to a previously announced $320 million concurrent private investment.
According to Avere, the two private placements, consisting of common stock and pre-funded warrants, are expected to close immediately prior to the completion of its all-stock merger with NextCure (Nasdaq: NXTC). Upon closing, Avere is expected to have 449,668,672 as-converted shares outstanding, and the combined proceeds are expected to fund its operating plan into 2029. The merged company is expected to operate as Avere Therapeutics and trade on Nasdaq under ticker AVRX.